Weekly Research Analysts’ Ratings Updates for Trevi Therapeutics (TRVI)

Several analysts have recently updated their ratings and price targets for Trevi Therapeutics (NASDAQ: TRVI):

• 7/25/2026 – Trevi Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
• 7/20/2026 – Trevi Therapeutics is now covered by BMO Capital Markets. They set an “outperform” rating and a $36.00 price target on the stock.
• 7/20/2026 – Trevi Therapeutics was upgraded by BMO Capital Markets to “strong-buy”.
• 7/20/2026 – Trevi Therapeutics had its price target raised by B. Riley Financial, Inc. from $21.00 to $31.00. They now have a “buy” rating on the stock.
• 7/20/2026 – Trevi Therapeutics had its price target raised by HC Wainwright from $21.00 to $24.00. They now have a “buy” rating on the stock.
• 7/17/2026 – Trevi Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 6/20/2026 – Trevi Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.